OncoPep Enters Exclusive License Agreement with Dana-Farber for Novel Therapeutic Multi-Peptide Vaccine Technology for Hematolog

OncoPep Enters Exclusive License Agreement with Dana-Farber for Novel Therapeutic Multi-Peptide Vaccine Technology for Hematologic Cancers
-- Multiple myeloma cells to be first target --

-- Phase 1/2a clinical trial to begin in 2012 --

BOSTON--(BUSINESS WIRE)--OncoPep, Inc. today announced that the company has entered into an exclusive, worldwide license agreement with Dana-Farber Cancer Institute for a multi-peptide therapeutic cancer vaccine technology. The first vaccine developed from this technology, PVX-410, is designed to target multiple myeloma cells. Financial terms of the agreement are undisclosed. A Phase 1/2a trial, in which PVX-410 will be studied in patients with smoldering multiple myeloma, is planned for 2012. Smoldering multiple myeloma is an asymptomatic precursor of multiple myeloma that is defined by the extent of multiple myeloma cells present.

 "We are committed to developing PVX-410, which is a therapeutic cancer vaccine developed to target multiple myeloma cells," said Doris Peterkin, Chief Executive Officer of OncoPep. "This license with Dana-Farber Cancer Institute not only sets the stage for our upcoming clinical trial, but also provides OncoPep with a novel underlying technology that will give the Company the opportunity to develop additional therapeutic vaccine candidates in the future."

PVX-410 was created in the lab of Dr. Kenneth Anderson at Dana-Farber. It is composed of four proprietary, synthetic peptides to form a therapeutic cancer vaccine, which is designed to target specific antigens found on the surface of multiple myeloma cells. PVX-410 has demonstrated the ability to stimulate a strong immune response against multiple myeloma cell lines and patient cells in vitro. Multiple myeloma is a cancer of the plasma cells for which there is currently no cure.

About OncoPep

 OncoPep is developing targeted immunotherapeutics to prevent the progression of cancer, prolong survival and restore the quality of life of patients. OncoPep's lead program is a multi-peptide therapeutic vaccine for use in treating smoldering multiple myeloma. www.oncopep.com

 MacDougall Biomedical Communications
Jennifer Conrad, 781-235-3060
[email protected]


Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.